Biotech Archives - Page 52 of 795

2 minute read

MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib

April 29, 12:36 PM

MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds despite setbacks.

MOR

1 minute read

Why Is Cancer Focused Deciphera Pharmaceuticals Stock Skyrocketing On Monday?

By Vandana Singh

April 29, 12:17 PM

ONO Pharmaceutical to acquire Deciphera Pharmaceuticals for $2.4B in cash. Deciphera brings specialized R&D in kinase drug discovery, commercial platforms, and a pipeline of cancer drugs including QINLOCK. Acquisition expected to close Q3 2024.

DCPH

2 minute read

FDA Approves X4 Pharmaceuticals’ Mavorixafor As First Therapy For Rare Immunodeficiency Disorder

By Vandana Singh

April 29, 12:10 PM

FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts. First therapy for this rare immunodeficiency disorder. Potential sales forecasted at $54.6M in 2024, rising to $450.9M by 2027.

XFOR

3 minute read

Molecular Partners Announces Publication In Cancer Immunology Research Of Preclinical Data Supporting MP0533’s Proposed Mechanism Of Action

By Benzinga Newsdesk

April 29, 11:01 AM

Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while sparing healthy cells Results highlight MP0533-mediated T-cell activation and tumor

MOLN

2 minute read

Johnson & Johnson-Partnered Addex Therapeutics’ Epilepsy Candidate Fails Mid-Stage Study, Stock Tanks

By Vandana Singh

April 29, 10:53 AM

Latest Phase 2 epilepsy study findings on ADX71149 adjunctive therapy for focal onset seizures. Partnered with Janssen, Addex Therapeutics evaluates treatment efficacy in patients with suboptimal response to standard care.

ADXN

5 minute read

Annovis Bio Announces Statistically Significant Phase II/III Data In Patients With Early Alzheimer’s Disease; Efficacy In The CGIC Endpoint Was Not Reached Due To The Limited Number Of Patients And Short Trial Duration

By Benzinga Newsdesk

April 29, 10:15 AM

Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild ADImprovement in cognition measured by ADAS-Cog 11 at three months is 3.3 points as

ANVS

2 minute read

TFF Pharmaceuticals Makes Available Phase 2 Data From Tacrolimus Inhalation Powder For The Prevention Of Lung Transplant Rejection Presented At The Recent ISHLT Annual Meeting

By Benzinga Newsdesk

April 29, 10:01 AM

Data Now Available on Company Website Following 8-K Filing Data Demonstrate that Treatment with TFF TAC Prevents Lung Transplant Rejection at Only One-sixth of the Dose of Oral Tacrolimus and at Two-thirds of the

TFFP

2 minute read

Double Good News For AstraZeneca’s Breast Cancer Drugs

By Vandana Singh

April 29, 9:25 AM

Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer.

AZN

3 minute read

GE HealthCare Receives FDA Clearance For Portrait VSM, Building In Its Growing Ecosystem Of Connected Patient Monitoring Solutions

By Benzinga Newsdesk

April 29, 9:13 AM

The portable vital signs monitor (VSM) adds to GE HealthCare's growing Portrait Ecosystem to help clinicians make timely treatment decisions and detect patient deterioration earlier with a streamlined spot check

GEHC

2 minute read

Atossa Therapeutics Announces Expanded Research Agreement With Weill Cornell Medicine To Further Evaluate Synergy Between Antibody Drug Conjugates And (Z)-Endoxifen

By Benzinga Newsdesk

April 29, 8:34 AM

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates (ADCs) and

ATOS